MMRN1 and colorectal carcinoma: Despite the promotion of FAK expression by the APC disruption‐linked MYC activation, [9] FAK may be largely activated in CRC through the ECM‐integrin engagement, as the pharmacological inhibitor targeting active FAK (VS‐6063) markedly impairs cell proliferation in several cell lines examined (Figure 3).